These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Myelodysplastic syndromes: biology and treatment. Jädersten M; Hellström-Lindberg E J Intern Med; 2009 Mar; 265(3):307-28. PubMed ID: 19141095 [TBL] [Abstract][Full Text] [Related]
25. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003 [TBL] [Abstract][Full Text] [Related]
26. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. Sekeres MA; Maciejewski JP; Giagounidis AA; Wride K; Knight R; Raza A; List AF J Clin Oncol; 2008 Dec; 26(36):5943-9. PubMed ID: 19018091 [TBL] [Abstract][Full Text] [Related]
27. Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management. Burgstaller S; Wiesinger P; Stauder R Drugs Aging; 2015 Nov; 32(11):891-905. PubMed ID: 26476843 [TBL] [Abstract][Full Text] [Related]
28. Management of myelodysplastic syndromes in adults: guidelines from the Belgian Haematological Society. Meers S; Breems D; Bries G; Delforge M; Graux C; Ravoet C; Selleslag D; Noens L; Acta Clin Belg; 2013; 68(4):253-62. PubMed ID: 24455794 [TBL] [Abstract][Full Text] [Related]
29. Treatment of low-risk myelodysplastic syndromes. Santini V Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):462-469. PubMed ID: 27913517 [TBL] [Abstract][Full Text] [Related]
30. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. Santini V; Almeida A; Giagounidis A; Gröpper S; Jonasova A; Vey N; Mufti GJ; Buckstein R; Mittelman M; Platzbecker U; Shpilberg O; Ram R; Del Cañizo C; Gattermann N; Ozawa K; Risueño A; MacBeth KJ; Zhong J; Séguy F; Hoenekopp A; Beach CL; Fenaux P J Clin Oncol; 2016 Sep; 34(25):2988-96. PubMed ID: 27354480 [TBL] [Abstract][Full Text] [Related]
39. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications. Stahl M; Zeidan AM Cancer; 2017 May; 123(10):1703-1713. PubMed ID: 28192601 [TBL] [Abstract][Full Text] [Related]